Low Remission Recapture After Ustekinumab Dose Optimization in CD: Results of the Randomized Placebo-Controlled Double-Blind REScUE Study.
出版信息
Gastroenterol Hepatol (N Y). 2025 Aug;21(7 Suppl 5):14-15.
Abstract
摘要
相似文献
1
Low Remission Recapture After Ustekinumab Dose Optimization in CD: Results of the Randomized Placebo-Controlled Double-Blind REScUE Study.
Gastroenterol Hepatol (N Y). 2025 Aug;21(7 Suppl 5):14-15.
2
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Cochrane Database Syst Rev. 2025 May 13;5(5):CD007572. doi: 10.1002/14651858.CD007572.pub4.
3
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Cochrane Database Syst Rev. 2015 May 5(5):CD007572. doi: 10.1002/14651858.CD007572.pub2.
4
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.
Lancet. 2025 Jul 26;406(10501):358-375. doi: 10.1016/S0140-6736(25)00681-6. Epub 2025 Jul 17.
5
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Cochrane Database Syst Rev. 2016 Nov 25;11(11):CD007572. doi: 10.1002/14651858.CD007572.pub3.
6
Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Inflamm Bowel Dis. 2023 Mar 1;29(3):367-375. doi: 10.1093/ibd/izac103.
7
Impact of immediate drug optimization of ustekinumab on medium term targets in Crohn's disease: results from the multicentre retrospective real-life study MUST.
Dig Liver Dis. 2025 Sep;57(9):1772-1777. doi: 10.1016/j.dld.2025.05.024. Epub 2025 Jun 7.
8
Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis.
Mayo Clin Proc. 2014 Dec;89(12):1621-35. doi: 10.1016/j.mayocp.2014.08.019. Epub 2014 Oct 29.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
10
Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Cochrane Database Syst Rev. 2019 Dec 12;12(12):CD012804. doi: 10.1002/14651858.CD012804.pub2.
本文引用的文献
1
Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2022 Dec;20(12):2728-2740.e1. doi: 10.1016/j.cgh.2021.10.002. Epub 2021 Oct 8.
2
Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e783-e788. doi: 10.1097/MEG.0000000000002256.
Zotero 插件